In preclinical studies, A2AR antagonists showed potential benefits in the treatment of some neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), neuroinflammation, ischemia, spinal cord injury, drug addiction and other conditions [31]. The gene discussed is ADORA2A; the disease is Parkinson disease.